Companies in #Inflammation

Antares Therapeutics is a clinical-stage small molecule biopharmaceutical company developing oral and injectable therapies for autoimmune and inflammatory diseases. The company is headquartered in Princeton, New Jersey, and was acquired by Novartis in 2026.

Avere Therapeutics is a clinical-stage immunology company developing drugs for autoimmune and inflammatory diseases. The company was formed from the former Akero Therapeutics team and entered the public markets via a reverse merger, also acquiring rights to a Hansoh Pharmaceutical drug for $120M.

Caldera Therapeutics is a privately held biopharmaceutical company developing targeted therapies for immunology and inflammation. In 2026, the company announced plans to go public via a reverse merger transaction raising approximately $478M collectively with Vidya Therapeutics.

Biotech developing disease-controlling treatments for COPD and other neutrophil-driven inflammatory respiratory diseases. Lead candidate EXPD-101 is an oral, once-daily DPP1 inhibitor advancing into a global Phase 2 COPD trial. Backed by Sanofi.

Incyte is a oncology / inflammation company. See today's news for the latest developments.

Biotech developing precision immunology and inflammation medicines, with a pipeline piece licensed from Kira Pharmaceuticals targeting the Tavneos (C5aR) space.

RayThera is a San Diego-based private biotech developing small-molecule therapeutics in immunology. Founded in 2023 with a $110M Series A, the company is being acquired by Biogen in a deal worth up to $1B, marking a major exit for the immunology-focused startup.

Swedish Orphan Biovitrum (Sobi) is a global specialty biopharmaceutical company focused on rare diseases, with a portfolio spanning hematology, immunology, and specialty care. The company markets hemophilia treatments (Eloctate, Alprolix), immunology products (Kineret, Gamifant), and specialty therapeutics, and is expanding its rare-disease pipeline through both internal R&D and acquisitions.